Molecular markers demonstrate diagnostic and prognostic value in the evaluation of myelodysplastic syndromes in cytopenia patients

被引：3
|
作者：
He, Rong [1 ]
Chiou, Jonathan [2 ]
Chiou, Allison [3 ]
Chen, Dong [1 ]
Chen, Constance P. [4 ]
Spethman, Caroline [5 ]
Bessonen, Kurt R. [1 ]
Oliveira, Jennifer L. [1 ]
Nguyen, Phuong L. [1 ]
Reichard, Kaaren K. [1 ]
Hoyer, James D. [1 ]
Althoff, Simon D. [1 ]
Roh, Dana J. [1 ]
Miller, Mechelle A. [1 ]
Yuan, Ji [1 ]
Olteanu, Horatiu [1 ]
Begna, Kebede [6 ]
Tefferi, Ayalew [6 ]
Alkhateeb, Hassan [6 ]
Patnaik, Mrinal M. [6 ]
Litzow, Mark R. [6 ]
Al-Kali, Aref [6 ]
Viswanatha, David S. [1 ]
机构：
[1] Mayo Clin, Coll Med, Div Hematopathol, Rochester, MN 55905 USA
[2] Dartmouth Coll, Hanover, NH USA
[3] Wellesley Coll, Wellesley, MA USA
[4] Univ Notre Dame, Coll Sci, Notre Dame, IN 46556 USA
[5] Univ Nebraska, Sch Med, Omaha, NE 68198 USA
[6] Mayo Clin, Coll Med, Div Hematol, Rochester, MN USA
来源：
BLOOD CANCER JOURNAL | 2022年 / 12卷 / 01期
关键词：
CLONAL HEMATOPOIESIS; MUTATIONS; MDS; RISK;
D O I：
10.1038/s41408-022-00612-w
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Clinical and Prognostic Characteristics of Myelodysplastic Syndromes in Young Patients in Argentina
    Castro, Maria
    Basquiera, Ana
    De Dios Soler, Marcela
    Novoa, Viviana
    Gonzalez, Jacqueline
    Enrico, Alicia
    Correa, Walter
    Garcia, Pablo
    Nucifora, Elsa
    Fantl, Dorotea
    Arbelbide, Jorge
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S263 - S263
  • [32] Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes
    Nazha, A.
    Al-Issa, K.
    Hamilton, B. K.
    Radivoyevitch, T.
    Gerds, A. T.
    Mukherjee, S.
    Adema, V.
    Zarzour, A.
    Abuhadra, N.
    Patel, B. J.
    Hirsch, C. M.
    Advani, A.
    Przychodzen, B.
    Carraway, H. E.
    Maciejewski, J. P.
    Sekeres, M. A.
    LEUKEMIA, 2017, 31 (12) : 2848 - 2850
  • [33] Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes defined by international consensus classification
    Lee, Wan-Hsuan
    Tsai, Ming-Tao
    Tsai, Cheng-Hong
    Tien, Feng-Ming
    Lo, Min-Yen
    Tseng, Mei-Hsuan
    Kuo, Yuan-Yeh
    Liu, Ming-Chih
    Yang, Yi-Tsung
    Chen, Jui-Che
    Tang, Jih-Luh
    Sun, Hsun-, I
    Chuang, Yi-Kuang
    Lin, Liang-In
    Chou, Wen-Chien
    Lin, Chien-Chin
    Hou, Hsin-An
    Tien, Hwei-Fang
    BLOOD CANCER JOURNAL, 2023, 13 (01)
  • [34] Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes
    Mukherjee, Sudipto
    Dong, Weichuan
    Schiltz, Nicholas K.
    Stange, Kurt C.
    Cullen, Jennifer
    Gerds, Aaron T.
    Carraway, Hetty E.
    Singh, Abhay
    Advani, Anjali S.
    Sekeres, Mikkael A.
    Koroukian, Siran M.
    ONCOLOGIST, 2023, 28 (10) : 901 - 910
  • [35] Diagnostic, prognostic and predictive relevance of molecular markers in gliomas
    Brandner, S.
    von Deimling, A.
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2015, 41 (06) : 694 - 720
  • [36] Prognostic impact of chromosomal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemia patients. A study by the spanish group of myelodysplastic syndromes
    Nomdedeu, Meritxell
    Calvo, Xavier
    Pereira, Arturo
    Carrio, Anna
    Sole, Francesc
    Luno, Elisa
    Cervera, Jose
    Vallespi, Teresa
    Munoz, Concha
    Gomez, Candida
    Arias, Amparo
    Such, Esperanza
    Sanz, Guillermo
    Grau, Javier
    Insunza, Andres
    Calasanz, Maria-Jose
    Ardanaz, Maria-Teresa
    Hernandez-Rivas, Jesus-Maria
    Azaceta, Gemma
    Alvarez, Sara
    Sanchez, Joaquin
    Martin, Maria-Luisa
    Bargay, Joan
    Gomez, Valle
    Cervero, Carlos-Javier
    Allegue, Maria-Jose
    Collado, Rosa
    Campo, Elias
    Esteve, Jordi
    Nomdedeu, Benet
    Costa, Dolors
    GENES CHROMOSOMES & CANCER, 2016, 55 (04) : 322 - 327
  • [37] How I use molecular genetic tests to evaluate patients who have or may have myelodysplastic syndromes
    Steensma, David P.
    BLOOD, 2018, 132 (16) : 1657 - 1663
  • [38] Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better?
    Zeidan, Amer M.
    Sekeres, Mikkael A.
    Wang, Xiao-Feng
    Al Ali, Najla
    Garcia-Manero, Guillermo
    Steensma, David P.
    Roboz, Gail
    Barnard, John
    Padron, Eric
    DeZern, Amy
    Maciejewski, Jaroslaw P.
    List, Alan F.
    Komrokji, Rami S.
    AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (11) : 1036 - 1040
  • [39] Molecular and Diagnostic Testing Patterns in Elderly Patients with Myelodysplastic Syndromes (MDS) in the Connect® MDS/AML Disease Registry
    George, Tracy I.
    Cogle, Christopher R.
    Garcia-Manero, Guillermo
    Grinblatt, David L.
    Komrokji, Rami S.
    Kurtin, Sandra E.
    Maciejewski, Jaroslaw P.
    Savona, Michael R.
    Scott, Bart L.
    Sekeres, Mikkael A.
    Steensma, David P.
    Flick, E. Dawn
    Kiselev, Pavel
    Louis, Chrystal U.
    Nifenecker, Melissa
    Swern, Arlene S.
    Foucar, Kathryn
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S315 - S315
  • [40] Prognostic value of indoleamine 2,3 dioxygenase in patients with higher-risk myelodysplastic syndromes treated with azacytidine
    Mueller-Thomas, Catharina
    Heider, Michael
    Piontek, Guido
    Schlensog, Martin
    Bassermann, Florian
    Kirchner, Thomas
    Germing, Ulrich
    Goetze, Katharina S.
    Rudelius, Martina
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 190 (03) : 361 - 370
12345